T
Torben Plesner
Researcher at University of Southern Denmark
Publications - 205
Citations - 11134
Torben Plesner is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Daratumumab & Multiple myeloma. The author has an hindex of 45, co-authored 186 publications receiving 9295 citations. Previous affiliations of Torben Plesner include University of Copenhagen & Finsen Laboratory.
Papers
More filters
Journal ArticleDOI
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
TL;DR: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Targeting CD38 with daratumumab monotherapy in multiple myeloma
Henk M. Lokhorst,Torben Plesner,Jacob P. Laubach,Hareth Nahi,Peter Gimsing,Markus Hansson,Monique C. Minnema,Ulrik Lassen,Ulrik Lassen,Jakub Krejcik,Antonio Palumbo,Niels W.C.J. van de Donk,Tahamtan Ahmadi,Imran Khan,Clarissa M. Uhlar,Jianping Wang,A. Kate Sasser,Nedjad Losic,Steen Lisby,Linda Basse,Nikolai Constantin Brun,Paul G. Richardson +21 more
TL;DR: Daratumumab monotherapy had a favorable safety profile and encouraging efficacy in patients with heavily pretreated and refractory myeloma, and no maximum tolerated dose was identified in part 1.
Journal ArticleDOI
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Antonio Palumbo,Roman Hájek,Michel Delforge,Martin Kropff,Maria Teresa Petrucci,John Catalano,Heinz Gisslinger,Wieslaw Wiktor-Jedrzejczak,Mamia Zodelava,Katya C Weisel,Nicola Cascavilla,Genadi Iosava,Michele Cavo,Janusz Kloczko,Joan Bladé,Meral Beksac,Ivan Spicka,Torben Plesner,Joergen Radke,Christian Langer,Dina Ben Yehuda,Alessandro Corso,Lindsay Herbein,Zhinuan Yu,Jay Mei,Christian Jacques,Meletios A. Dimopoulos +26 more
TL;DR: MPR-R significantly prolonged progression-free survival in patients with newly diagnosed multiple myeloma who were ineligible for transplantation, with the greatest benefit observed in patients 65 to 75 years of age.
Journal ArticleDOI
Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik,Jakub Krejcik,Tineke Casneuf,Inger S. Nijhof,Bie Verbist,Jaime Bald,Torben Plesner,Khaja Syed,Kevin Liu,Niels W.C.J. van de Donk,Brendan M. Weiss,Tahamtan Ahmadi,Henk M. Lokhorst,Tuna Mutis,A. Kate Sasser +14 more
TL;DR: Depletion of CD38(+) immunosuppressive cells, which is associated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR clonality, represents possible additional mechanisms of action for daratumumab and deserves further exploration.
Journal ArticleDOI
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Thierry Facon,Shaji Kumar,Torben Plesner,Robert Z. Orlowski,Philippe Moreau,Nizar J. Bahlis,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Hartmut Goldschmidt,Michael O'Dwyer,Aurore Perrot,Christopher P. Venner,Katja Weisel,Joseph R. Mace,Noopur Raje,Michel Attal,Mourad Tiab,Margaret Macro,Laurent Frenzel,Xavier Leleu,Tahamtan Ahmadi,Christopher Chiu,Jianping Wang,Rian Van Rampelbergh,Clarissa M. Uhlar,Rachel Kobos,Ming Qi,Saad Z. Usmani,Maia Trial Investigators +30 more
TL;DR: Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among thosewho received lenalidmide and Dexameth asone alone.